# Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

> **NCT00225212** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 35 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Diffuse Large Cell Lymphoma
- Mantle Cell Lymphoma
- Transformed Lymphoma
- Other Subtypes of B-cell Lymphoma
- Lymphoma

## Interventions

- **DRUG:** Rituximab 375 mg/m2

## Key facts

- **NCT ID:** NCT00225212
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-11
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2014-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225212, "Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00225212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*